OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press42210.17650/1818-8346-2020-15-2-92-107INFECTION PROBLEMS IN ONCOHEMATOLOGYПРОБЛЕМЫ ИНФЕКЦИЙ В ОНКОГЕМАТОЛОГИИCurrent treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignanciesСовременные возможности терапии инфекций, вызванных карбапенеморезистентными энтеробактериями, у больных с опухолями системы кровиhttps://orcid.org/0000-0001-5973-5763KlyasovaG. A.КлясоваГ. А.
Russian Federation

4 Novyy Zykovskiy Proezd, Moscow 125167

Галина Александровна Клясова

125167 Москва, Новый Зыковский проезд, 4

klyasova.g@blood.ruNational Research Center for Hematology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России16072020152921071507202015072020https://oncohematology.abvpress.ru/ongm/article/view/422

Infections are a common complication in patients with hematological malignancies, especially during neutropenia. Recently, an increase in multidrug-resistant gram-negative pathogens has been observed in the etiology of infectious complications, including carbapenem-resistant Enterobacteriaceae. However, therapeutic options for treatment of these infections are limited. The review represents treatment options for infections caused by carbapenem-resistant Enterobacteriaceae, including the use of reserve drugs such as polymyxin, carbapenems, tigecycline, as well as a new antibiotic – ceftazidime-avibactam, which contains a new β-lactamase inhibitor with unique properties.

Инфекции являются частыми осложнениями у больных с опухолями системы крови, особенно в период нейтропении. В последнее время в этиологии инфекционных осложнений наблюдается увеличение количества полирезистентных грамотрицательных возбудителей, включая карбапенеморезистентные энтеробактерии, возможность терапии которых ограничена. В обзоре представлены варианты лечения инфекций, вызванных карбапенеморезистентными энтеробактериями, включающие как применение противомикробных препаратов резерва, таких как полимиксин, карбапенемы, тигециклин, так и нового антибиотика цефтазидима-авибактама, в состав которого входит новый ингибитор β-лактамаз с уникальными свойствами.

carbapenem-resistant Enterobacteriaceaehaematological malignancycarbapenemasefebrile neutropeniaceftazidime-avibactamкарбапенеморезистентные энтеробактерииопухоль системы кровикарбапенемазыфебрильная нейтропенияцефтазидим-авибактамKlyasova G.A. Antimicrobial therapy. In: Program treatment of blood system diseases: collection of diagnostic algorithms and protocols for the treatment of blood system disorders. Ed.: V.G. Savchenko. Moscow: Praktika, 2012. Pp. 827–54. (In Russ.).Клясова Г.А. Антимикробная терапия. В кн.: Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2012. С. 827–54.Klyasova G.A., Speranskaya L.L., Mironova A.V. et al. The pathogens causing sepsis in immunocompromised patients: structure and problems of antibiotic resistance. Results of multicenter cooperative study. Gematologiya i transfuziologiya = Hematology and Transfusiology 2007;52(1):11–8. (In Russ.).Клясова Г.А., Сперанская Л.Л., Миронова А.В. и др. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования). Гематология и трансфузиология 2007;52(1):11–8.Puerta-Alcalde P., Cardozo C., Marco F. et al. Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. Bone Marrow Transplant 2020;55(3):603–12. DOI: 10.1038/s41409-019-0701-3.Klyasova G.A., Okhmat V.A. Antimicrobial therapy. In: Diagnostic algorithms and protocols for the treatment of blood system disorders. Ed.: V.G. Savchenko. Moscow: Praktika 2018. T. 2. Pp. 1067–1114. (In Russ.).Клясова Г.А., Охмат В.А. Антимикробная терапия. В кн.: Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика 2018. Том 2. C. 1067–1114.De Angelis G., Fiori B., Menchinelli G. et al. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007-2015). Eur J Clin Microbiol Infect Dis 2018;37(9):1627–36. DOI: 10.1007/s10096-018-3292-9.Pouch S.M., Satlin M.J. Carbapenemresistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence 2017;8(4):391–402. DOI: 10.1080/21505594.2016.1213472.Girmenia C., Rossolini G.M., Piciocchi A. et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015;50(2):282–8. DOI: 10.1038/bmt.2014.231.Trecarichi E.M., Pagano L., Martino B. et al. Bloodstream infections caused by Klebsiella pneumoniae in oncohematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol 2016;91(11):1076–81. DOI: 10.1002/ajh.24489.Klyasova G., Korobova A., Khrulnova S. et al. Trends in antimicrobial resistance in gram-negative pathogens among haematological patients: results of multicenter study. Abstract Book 2020 European Congress of Clinical Microbiology and Infectious Diseases 2020;4:4253.Averbuch D., Tridello G., Hoek J. et al. Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: Intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis 2017;13;65(11):1819–28. DOI: 10.1093/cid/cix646.Ambler R.P. The structure of betalactamases. Philos Trans R Soc Lond B Biol Sci 1980;289(1036):321–31.Sukhorukova M.V., Edelstein M.V., Ivanchik N.V. et al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016”. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy 2019;21(2):147–59. (In Russ.). DOI: 10.36488/cmac.2019.2.147-159.Сухорукова М.В., Эйдельштейн М.В., Иванчик Н.В. и др. Антибиотикорезистентность нозокомиальных штаммов Enterobacterales в стационарах России: результаты многоцентрового эпидемиологического исследования «МАРАФОН 2015–2016». Клиническая микробиология и антимикробная химиотерапия 2019;21(2):147–59. DOI: 10.36488/cmac.2019.2.147-159.Tzouvelekis L., Markogiannakis A., Psichogiou M. et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: anevolving crisis of global dimensions. Clin Microbiol Rev 2012;25:682–707. DOI: 10.1128/CMR.05035-11.Rodríguez-Bano J., Cisneros J.M., Cobos-Triguerosd N. et al. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enferm Infecc Microbiol Clin 2015;33(5):337.e1–21. DOI: 10.1016/j.eimc.2014.11.009.De Maio Carrilho C.M.D., Marques de Oliveira L., Gaudereto J. et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis 2016;16:629. DOI: 10.1186/s12879-016-1979-z.Tumbarello M., Trecarichi E.M., De Rosa F.G. et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015;70(7):2133–43. DOI: 10.1093/jac/dkv086.Gutiérrez-Gutiérrez B., Salamanca E., de Cueto M. et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017;7:726–34. DOI: 10.1016/S14733099(17)302281.Akova M., Daikos G.L., Tzouvelekis L., Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing gram-negative bacteria. Clin Microbiol Infect 2012;18(5):439–48. DOI: 10.1111/j.1469-0691.2012.03823.x.Daikos G.L., Tsaousi S., Tzouvelekis L.S. et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58(4):2322–8. DOI: 10.1128/AAC.02166-13.Endimiani A., Perez F., Bajaksouzian S. et al. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol 2010;48(12):4417–25. DOI: 10.1128/JCM.02458-09.Daikos G.L., Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (When) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17(8):1135–41. DOI: 10.1111/j.1469-0691.2011.03553.x.Beloborodov V.B., Gruver K.P. Carbapenems in modern clinical practice. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2012;18(17):1037–42. (In Russ.).Белобородов В.Б., Грувер К.П. Карбапенемы в современной клинической практике. Русский медицинский журнал 2012;18(17):1037–42.Sheu C.C., Chang Y.T., Lin S.Y. et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol 2019;30;10:80. DOI: 10.3389/fmicb.2019.00080.Tsuji B.T., Pogue J.M., Zavascki A.P. et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019;39(1):10–39. DOI: 10.1002/phar.2209.Bassetti M., Giacobbe D.R., Giamarellou H. et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect 2018;24(2):133–44. DOI: 10.1016/j.cmi.2017.08.030.Mashni O., Nazer L., Le J. Critical review of double-carbapenem therapy for the treatment of carbapenemaseproducing Klebsiella pneumoniae. Ann Pharmacother 2019;53(1):70–81. DOI: 10.1177/1060028018790573.Roberts J.A., Abdul-Aziz M.H., Davis J.S. et al. Continuous versus intermittent β-lactam infusion in severe sepsis: a metaanalysis of individual patient data from randomized trials. Am J Respir Crit Care Med 2016;15;194(6):681–91. DOI: 10.1164/rccm.201601-0024OC.Vardakas K.Z., Voulgaris G.L., Maliaros A. et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomized trials. Lancet Infect Dis 2018;18(1):108–20. DOI: 10.1016/S1473-3099(17)30615-1.Bulik C.C., Nicolau D.P. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55(6):3002–4. DOI: 10.1128/AAC.01420-10.De Pascale G., Martucci G., Montini L. et al. Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study. Crit Care 2017;21(1):173. DOI: 10.1186/s13054-017-1769-z.Oliva A., Scorzolini L., Castaldi D. et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenemresistant Klebsiella pneumoniae (CR-Kp). J Infect 2017;74(1):103–6. DOI: 10.1016/j.jinf.2016.10.002.Monaco M., Giani T., Raffone M. et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill 2014;23;19(42):20939. DOI: 10.2807/1560-7917.es2014.19.42.20939.Falagas M.E., Bliziotis I.A., Tam V.H. Intraventricular or intrathecal use of polymyxins in patients with gramnegative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007;29(1):9–25. DOI: 10.1016/j.ijantimicag.2006.08.024.Nation R.L., Garonzik S.M., Thamlikitkul V. et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis 2017;1;64(5):565–71. DOI: 10.1093/cid/ciw839.Eliseev E.V., Azizov I.S., Zubareva N.A. Review of the international consensus guidelines for the optimal use of the polymyxins. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy 2019;21(4):282–309. (In Russ.). DOI: 10.36488/cmac.2019.4.282-309. [Елисеев Е.В., Азизов И.С., Зубарева Н.А. Обзор международных согласительных рекомендаций по оптимальному использованию полимиксинов. Клиническая микробиология и антимикробная химиотерапия 2019;21(4):282–309. DOI: 10.36488/cmac.2019.4.282-309.Falagas M.E., Giannopoulou K.P., Kokolakis G.N., Rafailidis P.I. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069–77. DOI: 10.1086/527442.Samonis G., Maraki S., Karageorgopoulos D.E. et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012;31:695–701. DOI: 10.1007/s10096-011-1360-5.Parker S., Lipman J., Koulenti D. et al. What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. Int J Antimicrob Agents 2013;42:289–93. DOI: 10.1016/j.ijantimicag.2013.05.018.Le J., McKee B., Srisupha-Olarn W., Burgess D.S. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res 2011;3:106–10. DOI: 10.4021/jocmr551w.Tanaseanu C., Milutinovic S., Calistru P.I. et al. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009;9;9:44. DOI: 10.1186/1471-2466-9-44.Ramirez J., Dartois N., Gandjini H. et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-¬dosage tigecycline regimens versus imipenemcilastatin for treatment of hospitalacquired pneumonia. Antimicrob Agents Chemother 2013;57:1756–62. DOI: 10.1128/AAC.01232-12.De Pascale G., Montini L., Pennisi M. et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 2014;5;18(3):R90. DOI: 10.1186/cc13858.Moreno B.B., Simón I.F., García V.P. et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis 2014;46(3):175–80. DOI: 10.3109/00365548.2013.861608.Sbrana, F., Malacarne, P., Viaggi, B. et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013;56(5):697–700. DOI: 10.1093/cid/cis969.Di Carlo P., Gulotta G., Casuccio A. et al. KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol 2013;3;13(1):13. DOI: 10.1186/1471-2253-13-13.Geng T.T., Xu X., Huang M. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study. Medicine (Baltimore) 2018;97(8):e9961. DOI: 10.1097/MD.0000000000009961.Ni W., Han Y., Liu J. et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95(11):e3126. DOI: 10.1097/MD.0000000000003126.Kozlov R.S., Stetsyuk O.U., Andreeva I.V. Ceftazidime-avibactam: new rules for the game against multidrug-resistant gram-negative bacteria. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy 2018;20(1):24–34. (In Russ.). DOI: 10.36488/cmac.2018.1.24-34.Козлов Р.С., Стецюк О.У., Андреева И.В. Цефтазидим-авибактам: новые «правила игры» против полирезистентных грамотрицательных бактерий. Клиническая микробиология и антимикробная химиотерапия 2018;20(1):24–34. DOI: 10.36488/cmac.2018.1.24-34.Karlowsky J.A., Kazmierczak K.M., Bouchillon S.K. et al. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Latin American countries: results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother 2019;27;63(4):e01814–8. DOI: 10.1128/AAC.01814-18.De Jonge B.L.M., Karlowsky J.A., Kazmierczak K.M. et al. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 2016;22;60(5):3163–9. DOI: 10.1128/AAC.03042-15.Castón J.J., Lacort-Peralta I., MartínDávila P. et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis 2017;59:118–23. DOI: 10.1016/j.ijid.2017.03.021.Tumbarello M., Trecarichi E.M., Corona A. et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis 2019;68(3):355–64. DOI: 10.1093/cid/ciy492.Guimarãesa T., Nouérb S., Martinsc R. et al. Ceftazidime-avibactam as salvage therapy for infections caused by Enterobacteriales co-resistant to carbapenems and polymyxins. Antimicrob. Antimicrob Agents Chemother 2019;23;63(10):e00528–19. DOI: 10.1128/AAC.00528-19.van Duin D., Lok J.J., Earley M. et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018;6;66(2):163–71. DOI: 10.1093/cid/cix783.De la Calle C., Rodríguez O., Morata L. et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidimeavibactam. Int J Antimicrob Agents 2019;53(4):520–4. DOI: 10.1016/j.ijantimicag.2018.11.015.Sousa A., Pérez-Rodríguez T., Soto A. et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2018;73:3170–5. DOI: 10.1093/jac/dky295.Wenzler E., Deraedt M.F., Harrington A.T., Danizger L.H. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamaseproducing gram-negative pathogens. Diagn Microbiol Infect Dis 2017;88(4):352–4. DOI: 10.1016/j.diagmicrobio.2017.05.009.Shaw E., Rombauts A., Tubau F. et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2018;1;73(4):1104–6. DOI: 10.1093/jac/dkx496.Falcone M., Daikos G.L., Tiseo G. et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL-producing Enterobacterales. Clin Infect Dis 2020; 19;ciaa586. DOI: 10.1093/cid/ciaa586.Micozzi A., Gentile G., Minotti C. et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. BMC Infect Dis 2017;17(1):203. DOI: 10.1186/s12879-017-2297-9.Girmenia C., Bertaina A., Piciocchi A. et al. Incidence, risk Factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: An Italian prospective multicenter survey. Clin Infect Dis 2017;13;65(11):1884–96. DOI: 10.1093/cid/cix690.Forcina A., Baldan R., Marasco V. et al. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplant 2017;52(1):114–9. DOI: 10.1038/bmt.2016.234.Viale P., Tumietto F., Giannella M. et al. Impact of a hospital-wide multifaceted programme for reducing carbapenemresistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect 2015;21:242–7. DOI: 10.1016/j.cmi.2014.10.020.